American Journal of Clinical Dermatology

, Volume 14, Issue 4, pp 273–277 | Cite as

Pharmacotherapeutic Management of Actinic Keratosis: Focus on Newer Topical Agents

Review Article

Abstract

Actinic (solar) keratoses (AK) have the potential for malignant transformation and are the second most common diagnosis in dermatologic practices. No well-established clinical criteria are available to determine which AK are more likely to undergo malignant transformation; therefore, many dermatologists utilize field-directed approaches to treat all visible and subclinical AK on an affected skin surface. Current topical therapeutic agents require lengthy treatment regimens and are less well tolerated than many newer and investigational agents. We review and compare the efficacy and tolerability of well-established topical agents for the management of AK in the United States including 5-fluorouracil, imiquimod 5 % cream as well as the newer 2.5 and 3.75 % formulations, diclofenac 3 % gel, photodynamic therapy, and the recently approved ingenol mebutate gel and discuss the therapeutic potential of investigational agents. Cryotherapy and 5-fluorouracil are efficacious at treating AK but less tolerable than imiquimod cream, particularly at its lower concentrations. The newer agents, diclofenac gel and ingenol mebutate, appear to be more tolerable than cryotherapy and 5- fluorouracil; however, comparative studies regarding efficacy are not available.

References

  1. 1.
    Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89(5):241–50.PubMedGoogle Scholar
  2. 2.
    Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: commonly used field-directed and lesion-directed therapies. Cutis. 2012;89(6):294–301.PubMedGoogle Scholar
  3. 3.
    Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335–9.PubMedGoogle Scholar
  4. 4.
    Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(suppl 2):34–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil 0.5% cream for the treatment of actinic keratosis. Arch Dermatol. 2009;145:203–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Stockfleth E, Sterry W, Carey-Yard M, et al. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157(suppl 2):41–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Foley P, Merlin K, Cumming S, Campbell J, et al. A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol. 2011;10(12):1432–8.PubMedGoogle Scholar
  10. 10.
    Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11:195–201.PubMedGoogle Scholar
  11. 11.
    Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis: 10 + years of cumulative evidence of efficacy and safety. J Drugs Dermatol. 2012;11(5):600–8.PubMedGoogle Scholar
  12. 12.
    de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses [published correction in Br J Dermatol. 2008;158:873]. Br J Dermatol. 2007;156:222–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol. 2009;34(1):33–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156–9.PubMedGoogle Scholar
  15. 15.
    Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Campione E, Diluvio L, Paternò EJ, et al. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Huyke C, Reuter J, Rödig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7(2):128–33.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of DermatologyUniversity of California-Habor Medical CenterTorranceUSA
  2. 2.Department of DermatologyUniversity of Texas, SouthwesternDallasUSA
  3. 3.Department of PathologyUniversity of Texas, SouthwesternDallasUSA
  4. 4.Dermpath DiagnosticsDallasUSA

Personalised recommendations